Yan Zhang1, Xiaoli Su2, Fangfang Zou1, Tengjuan Xu1, Pinhua Pan1, Chengping Hu1. 1. Department of Respiratory Medicine, Xiangya Hospital, Key Cite of National Clinical Research Center for Respiratory Disease, Central South University, Changsha, 410008, Hunan, People's Republic of China. 2. Department of Respiratory Medicine, Xiangya Hospital, Key Cite of National Clinical Research Center for Respiratory Disease, Central South University, Changsha, 410008, Hunan, People's Republic of China. 1771980500@qq.com.
Abstract
BACKGROUND: Obstructive sleep apnea (OSA)-associated chronic kidney disease is mainly caused by chronic intermittent hypoxia (CIH) triggered renal damage. This study aims to investigate the role of toll-like receptor-4 (TLR4) in underlying mechanism involved chronic intermittent hypoxia (CIH)-induced renal damage. METHODS: C57BL/6J mice with normal TLR4 (TLR4 WT) or deficient TLR4 (TLR4 KO) were divided into four groups and exposed to normal air (NA) and CIH: TLR4 WT + NA, TLR4 KO + NA, TLR4 WT + CIH, and TLR4 KO + CIH. CIH lasted for 8 h/day and 7 days/week for 6 weeks. Renal injury and inflammation were evaluated by histology and ELISA. Renal tubular apoptosis, macrophages, and fibroblasts recruitment were determined by TUNEL assay, immunofluorescence, and western blot. RESULTS: In response to CIH, TLR4 deficiency alleviated renal histological injury, renal dysfunction, and fibrosis. TLR4 deficiency ameliorated renal dysfunction (serum BUN and creatinine) and tubular endothelial apoptosis determined by immunofluorescence staining of CD31 and TUNEL, and western blot of apoptotic protein (caspase-3, c-caspase-3, and Bax/Bcl-2 ratio). Furthermore, we also found TLR4 deficiency abrogated CIH-induced macrophages (CD68) and fibroblasts (α-SMA) recruitment, further reducing expression of extra-cellular matrix protein (collagen I and collagen IV) and inflammatory cytokines release (IL-6, TNF-α, and MCP-1). Finally, we used immunohistochemistry to demonstrate that TLR4 deficiency attenuated increased expression of MyD88 and NF-kB p65 after CIH treatment. CONCLUSIONS: Our data suggest that TLR4 plays a vital role in CIH-induced renal injury, inflammation and fibrosis, and inhibition of TLR4 probably provides a therapeutic potential for CIH-induced kidney damage.
BACKGROUND: Obstructive sleep apnea (OSA)-associated chronic kidney disease is mainly caused by chronic intermittent hypoxia (CIH) triggered renal damage. This study aims to investigate the role of toll-like receptor-4 (TLR4) in underlying mechanism involved chronic intermittent hypoxia (CIH)-induced renal damage. METHODS: C57BL/6J mice with normal TLR4 (TLR4 WT) or deficient TLR4 (TLR4 KO) were divided into four groups and exposed to normal air (NA) and CIH: TLR4 WT + NA, TLR4 KO + NA, TLR4 WT + CIH, and TLR4 KO + CIH. CIH lasted for 8 h/day and 7 days/week for 6 weeks. Renal injury and inflammation were evaluated by histology and ELISA. Renal tubular apoptosis, macrophages, and fibroblasts recruitment were determined by TUNEL assay, immunofluorescence, and western blot. RESULTS: In response to CIH, TLR4 deficiency alleviated renal histological injury, renal dysfunction, and fibrosis. TLR4deficiency ameliorated renal dysfunction (serum BUN and creatinine) and tubular endothelial apoptosis determined by immunofluorescence staining of CD31 and TUNEL, and western blot of apoptotic protein (caspase-3, c-caspase-3, and Bax/Bcl-2 ratio). Furthermore, we also found TLR4 deficiency abrogated CIH-induced macrophages (CD68) and fibroblasts (α-SMA) recruitment, further reducing expression of extra-cellular matrix protein (collagen I and collagen IV) and inflammatory cytokines release (IL-6, TNF-α, and MCP-1). Finally, we used immunohistochemistry to demonstrate that TLR4 deficiency attenuated increased expression of MyD88 and NF-kB p65 after CIH treatment. CONCLUSIONS: Our data suggest that TLR4 plays a vital role in CIH-induced renal injury, inflammation and fibrosis, and inhibition of TLR4 probably provides a therapeutic potential for CIH-induced kidney damage.
Authors: John J Sim; Scott A Rasgon; Dean A Kujubu; Victoria A Kumar; In Lu A Liu; Jiaxiao M Shi; Tam T Pham; Stephen F Derose Journal: Chest Date: 2008-11-24 Impact factor: 9.410
Authors: N M Isbel; P A Hill; R Foti; W Mu; L A Hurst; C Stambe; H Y Lan; R C Atkins; D J Nikolic-Paterson Journal: Kidney Int Date: 2001-08 Impact factor: 10.612
Authors: Huihua Li; Xiaoli Su; Xuebin Yan; Karla Wasserloos; Wei Chao; A Murat Kaynar; Zhao-Qian Liu; George D Leikauf; Bruce R Pitt; Li-Ming Zhang Journal: Anesthesiology Date: 2010-09 Impact factor: 7.892
Authors: Atsunori Nakao; Joao Seda Neto; Shinichi Kanno; Donna B Stolz; Kei Kimizuka; Fang Liu; Fritz H Bach; Timothy R Billiar; Augustine Mk Choi; Leo E Otterbein; Noriko Murase Journal: Am J Transplant Date: 2005-02 Impact factor: 8.086
Authors: Kinga A Powers; Katalin Szászi; Rachel G Khadaroo; Patrick S Tawadros; John C Marshall; András Kapus; Ori D Rotstein Journal: J Exp Med Date: 2006-07-17 Impact factor: 14.307
Authors: Cristina Vázquez-Carballo; Melania Guerrero-Hue; Cristina García-Caballero; Sandra Rayego-Mateos; Lucas Opazo-Ríos; José Luis Morgado-Pascual; Carmen Herencia-Bellido; Mercedes Vallejo-Mudarra; Isabel Cortegano; María Luisa Gaspar; Belén de Andrés; Jesús Egido; Juan Antonio Moreno Journal: Int J Mol Sci Date: 2021-01-15 Impact factor: 5.923